Merck’s established partnership with Moderna on the intismeran autogene personalized mRNA cancer vaccine, reinforced by positive Phase 3 melanoma data in August 2026 that drove sharp share gains for both companies, underpins the 98.9% market-implied probability against an acquisition announcement this year. The firms share costs and profits on the program without altering corporate structures, while Merck pursues separate deals such as its Bio-Techne acquisition to expand life sciences capabilities. Trader consensus reflects the absence of any disclosed merger discussions or financial catalysts necessitating a takeover, consistent with historical precedent for large pharma-biotech collaborations remaining at the alliance level. Tail risks include an abrupt strategic pivot by either board amid Keytruda patent pressures or Moderna’s post-COVID revenue contraction, though no such signals have emerged through mid-September.